Single Source: Post-Stroke Vascular Contributions to Cognitive Impairment and Dementia (VCID) in the United States (U19 - Clinical Trial Not Allowed)
About
This is a non-competitive funding opportunity intended to fund a single award. The National Institute of Neurological Disorders and Stroke is announcing its intent to issue a single source cooperative agreement award to Massachusetts General Hospital to support the renewal of the Post-Stroke Vascular Cognitive Impairment & Dementia (VCID) program, an ongoing, multi-site clinical research initiative designed to elucidate mechanisms linking stroke to subsequent cognitive impairment and dementia. The award will enable completion of the scientific aims initiated under the original U19 cooperative agreement (RFA-NS-19-012) and advance national priorities described in the National Plan to Address Alzheimer"s Disease. This is a Notice of Funding Opportunity (NOFO) for a Single Source that will invite an application from Massachusetts General Hospital. Please see Section III. Eligibility for additional information. In accordance with NIH standard peer-review processes, the application will be peer-reviewed, and only meritorious application(s) will be considered for funding.
This is a single-source cooperative agreement award opportunity specifically designed for Massachusetts General Hospital to continue and expand the Post-Stroke Vascular Cognitive Impairment and Dementia (VCID) research program. This prestigious National Institute of Neurological Disorders and Stroke (NINDS) funding opportunity supports multi-site clinical research initiatives focused on understanding the mechanisms that link stroke to subsequent cognitive impairment and dementia. The program is intended to complete scientific aims initiated under the original U19 cooperative agreement while advancing national priorities outlined in the National Plan to Address Alzheimer's Disease. This is a highly specialized research funding opportunity for institutions conducting longitudinal clinical studies and basic research on post-stroke cognitive outcomes. Researchers and institutions involved in stroke neurology, cognitive impairment, dementia research, and vascular contributions to neurological decline should be aware of this opportunity. The research aims to advance understanding of how cerebrovascular events contribute to long-term cognitive health and neurological outcomes. This renewal award demonstrates continued federal commitment to understanding stroke-related dementia and developing interventions to mitigate cognitive decline in stroke survivors. Organizations engaged in related research initiatives may benefit from understanding the priorities and mechanisms of this major research investment.
Funding Facts
● Applications openDeadline
September 28, 2026
Who can apply
Last verified July 5, 2026 · Source: Grants.gov
Grant Details
Funding Range
Not publicly specified
Deadline
2026-09-28
Grant Type
federal
Application Cycle
Single-Source, Non-Competitive (Designated Applicant Only)
Best For
Massachusetts General Hospital and affiliated multi-site clinical research institutions conducting post-stroke cognitive impairment and dementia research
Eligibility
Refer to Section III. Eligibility Information in the NOFO for additional information on eligibility.Only those who received a grant award under RFA-NS-19-012 are eligible to apply. Only the following applicant is eligible to apply for this single source funding: Massachusetts General Hospital. Foreign Organizations/International Collaborations:Non-domestic (non-U.S.) Entities (Foreign Organization
Frequently Asked Questions
Who is eligible for Single Source: Post-Stroke Vascular Contributions to Cognitive Impairment and Dementia (VCID) in the United States (U19 - Clinical Trial Not Allowed)?
This is a single-source funding opportunity with restricted eligibility. Only Massachusetts General Hospital is eligible to apply, as it is the designated recipient institution for this renewal award. Eligibility is limited to organizations that received a grant award under the original RFA-NS-19-012. Non-domestic (non-U.S.) entities may be included as foreign collaborators. For detailed eligibility requirements, refer to Section III of the Notice of Funding Opportunity (NOFO) on the official NIH/NINDS website.
How much funding does Single Source: Post-Stroke Vascular Contributions to Cognitive Impairment and Dementia (VCID) in the United States (U19 - Clinical Trial Not Allowed) provide?
The specific funding amount for this award has not been publicly disclosed in the available information. As a U19 cooperative agreement award, the funding is substantial and designed to support multi-site clinical research operations. For current funding details and budget information, contact the National Institute of Neurological Disorders and Stroke (NINDS) directly or consult the official NOFO.
How do I apply for Single Source: Post-Stroke Vascular Contributions to Cognitive Impairment and Dementia (VCID) in the United States (U19 - Clinical Trial Not Allowed)?
Since this is a single-source, non-competitive funding opportunity, only Massachusetts General Hospital may submit an application. The application will undergo standard NIH peer-review processes, and only meritorious applications will be considered for funding. All applicants must follow standard NIH application procedures and requirements outlined in the NOFO. Consult the official Notice of Funding Opportunity (NOFO) on the NIH grants website for specific application instructions, required forms, and submission procedures.
What can Single Source: Post-Stroke Vascular Contributions to Cognitive Impairment and Dementia (VCID) in the United States (U19 - Clinical Trial Not Allowed) funding be used for?
Funding supports the continuation and completion of the Post-Stroke Vascular Cognitive Impairment and Dementia (VCID) research program, a multi-site clinical research initiative. Resources support research designed to elucidate the mechanisms linking stroke to subsequent cognitive impairment and dementia. Note that clinical trials are not allowed under this funding mechanism. The award enables completion of scientific aims from the original U19 award while advancing national priorities in Alzheimer's disease research as outlined in the National Plan to Address Alzheimer's Disease.
Last updated: July 5, 2026